NasdaqCM - Delayed Quote USD

Genprex, Inc. (GNPX)

2.1200 -0.0900 (-4.07%)
At close: April 25 at 4:00 PM EDT
2.1800 +0.06 (+2.83%)
After hours: April 25 at 7:13 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. John Rodney Varner Co-Founder, Chairman, President & CEO 886.97k -- 1957
Mr. Ryan M. Confer M.S. Chief Financial Officer 606.57k -- 1982
Mr. David M. Schloss Senior Vice President of Human Resources -- -- --
Mr. Thomas C. Gallagher Esq. Senior Vice President of Intellectual Property & Licensing -- -- --
Dr. Mark S. Berger M.D. Chief Medical Officer -- -- 1955
Dr. Suzanne Thornton-Jones Senior Vice President of Regulatory Affairs & Quality -- -- --
Dr. Jack A. Roth F.A.C.S., M.D. Chairman of Scientific & Medical Advisory Board -- -- --

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679 https://www.genprex.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
26

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 22, 2024 - May 26, 2024
Genprex, Inc. Earnings Call

Related Tickers

CRDF Cardiff Oncology, Inc.
3.9900
-4.55%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9800
-1.32%
 
EDSA Edesa Biotech, Inc.
4.4684
+2.25%
 
ATNM Actinium Pharmaceuticals, Inc.
6.56
-7.08%
 
COCP Cocrystal Pharma, Inc.
1.5100
+0.67%
 
THTX Theratechnologies Inc.
1.3000
-7.80%
 
FBIO Fortress Biotech, Inc.
1.7200
-3.91%
 
CRVO CervoMed Inc.
24.99
+1.59%
 
CTXR Citius Pharmaceuticals, Inc.
0.7326
+2.25%
 
ENSC Ensysce Biosciences, Inc.
0.5467
-2.13%